{"disease":{"id":"uveal-melanoma","name":"uveal melanoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05733728","title":"Retrospective Register for Uveal Melanoma","phase":"","overall_status":"RECRUITING","enrollment_count":1400,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT05812027","title":"A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1150,"lead_sponsor_name":"TScan Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01989572","title":"Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":815,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04424719","title":"Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)","phase":"NA","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT04792463","title":"Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Mohamed Abdel-Rahman","has_results":false},{"nct_id":"NCT05377957","title":"Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT05987332","title":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":420,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT03070392","title":"Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":378,"lead_sponsor_name":"Immunocore Ltd","has_results":true},{"nct_id":"NCT05075993","title":"Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":352,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04025424","title":"Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)","phase":"","overall_status":"UNKNOWN","enrollment_count":350,"lead_sponsor_name":"Russian Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04577742","title":"Uveal Melanoma and Brachytheraphy: Long-term Outcomes.","phase":"","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Federico II University","has_results":false},{"nct_id":"NCT03947385","title":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":336,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT02843386","title":"Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":302,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT06073548","title":"Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study","phase":"","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT03611868","title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT02068586","title":"Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":210,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT01983748","title":"Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"University Hospital Erlangen","has_results":false},{"nct_id":"NCT03752398","title":"A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":198,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT04802876","title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"SOLTI Breast Cancer Research Group","has_results":false},{"nct_id":"NCT06022029","title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"OncoNano Medicine, Inc.","has_results":false},{"nct_id":"NCT04728113","title":"Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether)","phase":"NA","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT05907954","title":"(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":160,"lead_sponsor_name":"IDEAYA Biosciences","has_results":false},{"nct_id":"NCT01430416","title":"Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02570308","title":"A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":146,"lead_sponsor_name":"Immunocore Ltd","has_results":true},{"nct_id":"NCT04118062","title":"Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)","phase":"NA","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT06075589","title":"Psychoeducation for Uveal Melanoma","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":108,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02601378","title":"A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":107,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06007690","title":"A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Aura Biosciences","has_results":false},{"nct_id":"NCT05502900","title":"Adjuvant Melatonin for Uveal Melanoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Gustav Stalhammar","has_results":false},{"nct_id":"NCT03635632","title":"C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":94,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT07406724","title":"HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":90,"lead_sponsor_name":"Qingdao Sino-Cell Biomedicine Co., Ltd.","has_results":false},{"nct_id":"NCT02874040","title":"Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser)","phase":"NA","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT03746431","title":"A Phase 1 Study of [225Ac]-FPI-1434 Injection","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"Fusion Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT04879017","title":"FHD-286 in Subjects With Metastatic Uveal Melanoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":76,"lead_sponsor_name":"Foghorn Therapeutics Inc.","has_results":false},{"nct_id":"NCT03025256","title":"Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04935229","title":"Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":67,"lead_sponsor_name":"TriSalus Life Sciences, Inc.","has_results":false},{"nct_id":"NCT01585194","title":"Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06805825","title":"A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Novelty Nobility, Inc.","has_results":false},{"nct_id":"NCT05415072","title":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":66,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06932757","title":"Adjuvant Quisinostat in High-Risk Uveal Melanoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":63,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT05585034","title":"Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT03052127","title":"Study in Subjects With Small Primary Choroidal Melanoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Aura Biosciences","has_results":true},{"nct_id":"NCT02519322","title":"Neoadjuvant and Adjuvant Checkpoint Blockade","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT05282901","title":"Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":51,"lead_sponsor_name":"Institut Curie","has_results":false},{"nct_id":"NCT06284512","title":"Uveal Melanoma - Comparative Study","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT04645680","title":"Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03297424","title":"A Study of PLX2853 in Advanced Malignancies.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Opna Bio LLC","has_results":false},{"nct_id":"NCT01473004","title":"SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Thomas Jefferson University","has_results":true},{"nct_id":"NCT01835145","title":"Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06070012","title":"Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"Diwakar Davar","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}